Other anticoagulants (e.g. apixaban, rivaroxaban, dabigatran, heparin)

This comparative assessment concluded that apixaban has lower risks of major bleeding than dabigatran and rivaroxaban while providing similar efficacy in preventing stroke in adults with nonvalvular atrial fibrillation. The analysis reinforces that apixaban offers a more favorable balance of effectiveness and safety among commonly used DOACs in broadly stable outpatient populations.

This article reviews major randomized trials of dabigatran, rivaroxaban, and apixaban, showing that all three reduce stroke or systemic embolism compared with warfarin, with apixaban and dabigatran demonstrating significant reductions in hemorrhagic stroke and lower intracranial bleeding rates. It emphasizes that, in generally stable adult patients with atrial fibrillation, these agents provide effective anticoagulation with more favorable safety profiles than warfarin.

Using indirect comparative effectiveness methods based on large randomized trials, this study estimated lifetime stroke, systemic embolism, major hemorrhage, and survival outcomes for patients treated with apixaban, dabigatran, rivaroxaban, or warfarin. It found that apixaban provided the largest reduction in stroke or systemic embolism and major hemorrhagic events and extended life expectancy more than dabigatran or rivaroxaban in typical adult atrial fibrillation populations.

In a large real‑world cohort of Asian adults with nonvalvular atrial fibrillation, all standard‑ and low‑dose DOACs were associated with lower risks of ischemic stroke or systemic embolism, intracranial hemorrhage, major gastrointestinal bleeding, overall major bleeding, and all‑cause mortality compared with warfarin. Standard‑dose apixaban showed particularly low rates of thromboembolic events, major bleeding, and mortality, supporting its favorable benefit–risk profile in routine practice.

This comparative assessment concluded that apixaban has lower risks of major bleeding than dabigatran and rivaroxaban while providing similar efficacy in preventing stroke in adults with nonvalvular atrial fibrillation. The analysis reinforces that apixaban offers a more favorable balance of effectiveness and safety among commonly used DOACs in broadly stable outpatient populations.

In a large real‑world cohort of Asian adults with nonvalvular atrial fibrillation, all standard‑ and low‑dose DOACs were associated with lower risks of ischemic stroke or systemic embolism, intracranial hemorrhage, major gastrointestinal bleeding, overall major bleeding, and all‑cause mortality compared with warfarin. Standard‑dose apixaban showed particularly low rates of thromboembolic events, major bleeding, and mortality, supporting its favorable benefit–risk profile in routine practice.

Using indirect comparative effectiveness methods based on large randomized trials, this study estimated lifetime stroke, systemic embolism, major hemorrhage, and survival outcomes for patients treated with apixaban, dabigatran, rivaroxaban, or warfarin. It found that apixaban provided the largest reduction in stroke or systemic embolism and major hemorrhagic events and extended life expectancy more than dabigatran or rivaroxaban in typical adult atrial fibrillation populations.

This article reviews major randomized trials of dabigatran, rivaroxaban, and apixaban, showing that all three reduce stroke or systemic embolism compared with warfarin, with apixaban and dabigatran demonstrating significant reductions in hemorrhagic stroke and lower intracranial bleeding rates. It emphasizes that, in generally stable adult patients with atrial fibrillation, these agents provide effective anticoagulation with more favorable safety profiles than warfarin.

This comparative assessment concluded that apixaban has lower risks of major bleeding than dabigatran and rivaroxaban while providing similar efficacy in preventing stroke in adults with nonvalvular atrial fibrillation. The analysis reinforces that apixaban offers a more favorable balance of effectiveness and safety among commonly used DOACs in broadly stable outpatient populations.

This article reviews major randomized trials of dabigatran, rivaroxaban, and apixaban, showing that all three reduce stroke or systemic embolism compared with warfarin, with apixaban and dabigatran demonstrating significant reductions in hemorrhagic stroke and lower intracranial bleeding rates. It emphasizes that, in generally stable adult patients with atrial fibrillation, these agents provide effective anticoagulation with more favorable safety profiles than warfarin.

Using indirect comparative effectiveness methods based on large randomized trials, this study estimated lifetime stroke, systemic embolism, major hemorrhage, and survival outcomes for patients treated with apixaban, dabigatran, rivaroxaban, or warfarin. It found that apixaban provided the largest reduction in stroke or systemic embolism and major hemorrhagic events and extended life expectancy more than dabigatran or rivaroxaban in typical adult atrial fibrillation populations.

In a large real‑world cohort of Asian adults with nonvalvular atrial fibrillation, all standard‑ and low‑dose DOACs were associated with lower risks of ischemic stroke or systemic embolism, intracranial hemorrhage, major gastrointestinal bleeding, overall major bleeding, and all‑cause mortality compared with warfarin. Standard‑dose apixaban showed particularly low rates of thromboembolic events, major bleeding, and mortality, supporting its favorable benefit–risk profile in routine practice.

This comparative assessment concluded that apixaban has lower risks of major bleeding than dabigatran and rivaroxaban while providing similar efficacy in preventing stroke in adults with nonvalvular atrial fibrillation. The analysis reinforces that apixaban offers a more favorable balance of effectiveness and safety among commonly used DOACs in broadly stable outpatient populations.

In a large real‑world cohort of Asian adults with nonvalvular atrial fibrillation, all standard‑ and low‑dose DOACs were associated with lower risks of ischemic stroke or systemic embolism, intracranial hemorrhage, major gastrointestinal bleeding, overall major bleeding, and all‑cause mortality compared with warfarin. Standard‑dose apixaban showed particularly low rates of thromboembolic events, major bleeding, and mortality, supporting its favorable benefit–risk profile in routine practice.

Using indirect comparative effectiveness methods based on large randomized trials, this study estimated lifetime stroke, systemic embolism, major hemorrhage, and survival outcomes for patients treated with apixaban, dabigatran, rivaroxaban, or warfarin. It found that apixaban provided the largest reduction in stroke or systemic embolism and major hemorrhagic events and extended life expectancy more than dabigatran or rivaroxaban in typical adult atrial fibrillation populations.

This article reviews major randomized trials of dabigatran, rivaroxaban, and apixaban, showing that all three reduce stroke or systemic embolism compared with warfarin, with apixaban and dabigatran demonstrating significant reductions in hemorrhagic stroke and lower intracranial bleeding rates. It emphasizes that, in generally stable adult patients with atrial fibrillation, these agents provide effective anticoagulation with more favorable safety profiles than warfarin.

In a large real‑world cohort of Asian adults with nonvalvular atrial fibrillation, all standard‑ and low‑dose DOACs were associated with lower risks of ischemic stroke or systemic embolism, intracranial hemorrhage, major gastrointestinal bleeding, overall major bleeding, and all‑cause mortality compared with warfarin. Standard‑dose apixaban showed particularly low rates of thromboembolic events, major bleeding, and mortality, supporting its favorable benefit–risk profile in routine practice.